Axon Enterprise (NASDAQ:AXON) Research Coverage Started at UBS Group

UBS Group assumed coverage on shares of Axon Enterprise (NASDAQ:AXON) in a research note issued to investors on Wednesday morning, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $820.00 target price on the biotechnology company’s stock.

Several other analysts have also recently issued reports on the company. Bank of America increased their target price on Axon Enterprise from $750.00 to $895.00 and gave the stock a “buy” rating in a research report on Wednesday, June 4th. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. Wolfe Research initiated coverage on Axon Enterprise in a research report on Monday, July 7th. They set an “outperform” rating for the company. Barclays increased their target price on Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th. Finally, Needham & Company LLC increased their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $763.75.

Axon Enterprise Trading Up 1.4%

NASDAQ AXON opened at $756.09 on Wednesday. Axon Enterprise has a 12 month low of $279.02 and a 12 month high of $830.21. The stock has a market cap of $58.86 billion, a P/E ratio of 182.63, a P/E/G ratio of 85.86 and a beta of 1.29. The stock’s fifty day moving average price is $763.54 and its 200-day moving average price is $645.61. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm had revenue of $603.63 million for the quarter, compared to analysts’ expectations of $585.67 million. During the same period in the prior year, the firm posted $1.15 earnings per share. The company’s quarterly revenue was up 31.3% on a year-over-year basis. As a group, equities analysts forecast that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CRO Cameron Brooks sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $740.76, for a total value of $2,222,280.00. Following the completion of the sale, the executive directly owned 19,447 shares of the company’s stock, valued at $14,405,559.72. This trade represents a 13.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Joshua Isner sold 905 shares of the firm’s stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total value of $702,632.95. Following the completion of the sale, the president directly owned 268,735 shares of the company’s stock, valued at $208,643,166.65. The trade was a 0.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,642 shares of company stock worth $30,500,428. 4.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Axon Enterprise

Several institutional investors have recently modified their holdings of the stock. LaSalle St. Investment Advisors LLC lifted its stake in shares of Axon Enterprise by 2.1% in the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock valued at $408,000 after purchasing an additional 16 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Axon Enterprise by 5.0% in the first quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 18 shares during the period. Pinion Investment Advisors LLC increased its stake in Axon Enterprise by 3.0% in the first quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 19 shares during the period. Kentucky Retirement Systems increased its stake in Axon Enterprise by 0.4% in the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company’s stock worth $2,605,000 after purchasing an additional 19 shares during the period. Finally, WCM Investment Management LLC increased its stake in Axon Enterprise by 0.8% in the first quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company’s stock worth $1,306,000 after purchasing an additional 19 shares during the period. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.